Creation of Big Data repositories is now emphasized at virtually all research institutions and the NIH, but the number of publications describing patient outcomes from these sources appears modest.1 Why is this so; what factors limit what should be a hugely productive resource, and how can we improve the impact of this use of Big Data? Why does this issue require greater physician engagement and understanding to solve? The integration of clinical, laboratory, and financial data is required to describe disease and treatment outcomes as well as treatment value.
In this episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher of The Cancer Letter, Jacquelyn Cobb, managing editor, discuss the Sept. 23 meeting of the FDA Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee, during which the panel voted in favor of Galleri, the multi-cancer detection test from GRAIL Inc., to become the first multi-cancer detection test to receive regulatory approval.
